View Item 

Show simple item record

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis
dc.contributor.authorVerstovsek, Srdanen_US
dc.contributor.authorMesa, Ruben A.en_US
dc.contributor.authorGotlib, Jasonen_US
dc.contributor.authorLevy, Richard S.en_US
dc.contributor.authorGupta, Vikasen_US
dc.contributor.authorDiPersio, John F.en_US
dc.contributor.authorCatalano, John V.en_US
dc.contributor.authorDeininger, Michaelen_US
dc.contributor.authorMiller, Caroleen_US
dc.contributor.authorSilver, Richard T.en_US
dc.contributor.authorTalpaz, Mosheen_US
dc.contributor.authorWinton, Elliott F.en_US
dc.contributor.authorHarvey, Jimmie H.en_US
dc.contributor.authorArcasoy, Murat O.en_US
dc.contributor.authorHexner, Elizabethen_US
dc.contributor.authorLyons, Roger M.en_US
dc.contributor.authorPaquette, Ronalden_US
dc.contributor.authorRaza, Azraen_US
dc.contributor.authorVaddi, Krisen_US
dc.contributor.authorErickson‐viitanen, Susanen_US
dc.contributor.authorSun, Williamen_US
dc.contributor.authorSandor, Victoren_US
dc.contributor.authorKantarjian, Hagop M.en_US
dc.date.accessioned2013-05-02T19:35:26Z
dc.date.available2014-07-01T15:53:38Zen_US
dc.date.issued2013-05en_US
dc.identifier.citationVerstovsek, Srdan; Mesa, Ruben A.; Gotlib, Jason; Levy, Richard S.; Gupta, Vikas; DiPersio, John F.; Catalano, John V.; Deininger, Michael; Miller, Carole; Silver, Richard T.; Talpaz, Moshe; Winton, Elliott F.; Harvey, Jimmie H.; Arcasoy, Murat O.; Hexner, Elizabeth; Lyons, Roger M.; Paquette, Ronald; Raza, Azra; Vaddi, Kris; Erickson‐viitanen, Susan ; Sun, William; Sandor, Victor; Kantarjian, Hagop M. (2013). "The clinical benefit of ruxolitinib across patient subgroups: analysis of a placeboâ controlled, Phase III study in patients with myelofibrosis." British Journal of Haematology 161(4): 508-516. <http://hdl.handle.net/2027.42/97529>en_US
dc.identifier.issn0007-1048en_US
dc.identifier.issn1365-2141en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/97529
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherSubgroupsen_US
dc.subject.otherSpleen Volumeen_US
dc.subject.otherSymptomsen_US
dc.subject.otherRuxolitiniben_US
dc.subject.otherMyelofibrosisen_US
dc.titleThe clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid23480528en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/97529/1/bjh12274.pdf
dc.identifier.doi10.1111/bjh.12274en_US
dc.identifier.sourceBritish Journal of Haematologyen_US
dc.identifier.citedreferenceBarosi, G., Mesa, R.A., Thiele, J., Cervantes, F., Campbell, P.J., Verstovsek, S., Dupriez, B., Levine, R.L., Passamonti, F., Gotlib, J., Reilly, J.T., Vannucchi, A.M., Hanson, C.A., Solberg, L.A., Orazi, A., Tefferi, A. & International Working Group for Myelofibrosis Research Treatment (IWG‐MR). ( 2008 ) Proposed criteria for the diagnosis of post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia, 22, 437 – 438.en_US
dc.identifier.citedreferenceCervantes, F., Pereira, A., Esteve, J., Rafel, M., Cobo, F., Rozman, C. & Montserrat, E. ( 1997 ) Identification of ‘short‐lived’ and ‘long‐lived’ patients at presentation of idiopathic myelofibrosis. British Journal of Haematology, 97, 635 – 640.en_US
dc.identifier.citedreferenceBarbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.J., Kroger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S., Tefferi, A. & European Leukemia Net. ( 2011 ) Philadelphia‐negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology, 29, 761 – 770.en_US
dc.identifier.citedreferenceVerstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, Jr J.H., Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson‐Viitanen, S., Koumenis, I.L., Sun, W., Sandor, V. & Kantarjian, H.M. ( 2012 ) A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366, 799 – 807.en_US
dc.identifier.citedreferenceVerstovsek, S. ( 2009 ) Therapeutic potential of JAK2 inhibitors. Hematology/the Education Program of the American Society of Hematology, 636 – 642.en_US
dc.identifier.citedreferenceVardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom‐Lindberg, E., Tefferi, A. & Bloomfield, C.D. ( 2009 ) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937 – 951.en_US
dc.identifier.citedreferenceVainchenker, W., Delhommeau, F., Constantinescu, S.N. & Bernard, O.A. ( 2011 ) New mutations and pathogenesis of myeloproliferative neoplasms. Blood, 118, 1723 – 1735.en_US
dc.identifier.citedreferenceVainchenker, W., Dusa, A. & Constantinescu, S.N. ( 2008 ) JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Seminars in Cell and Developmental Biology, 19, 385 – 393.en_US
dc.identifier.citedreferenceTefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T. & Pardanani, A. ( 2011 ) Circulating interleukin (IL)‐8, IL‐2R, IL‐12, and IL‐15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. Journal of Clinical Oncology, 29, 1356 – 1363.en_US
dc.identifier.citedreferenceTefferi, A. & Vardiman, J.W. ( 2008 ) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point‐of‐care diagnostic algorithms. Leukemia, 22, 14 – 22.en_US
dc.identifier.citedreferenceTefferi, A. ( 2011 ) How I treat myelofibrosis. Blood, 117, 3494 – 3504.en_US
dc.identifier.citedreferenceTefferi, A. ( 2000 ) Myelofibrosis with myeloid metaplasia. New England Journal of Medicine, 342, 1255 – 1265.en_US
dc.identifier.citedreferenceSecond International Study of Infarct Survival (ISIS‐2) Collaborative Group. ( 1988 ) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‐2. Lancet, 2, 349 – 360.en_US
dc.identifier.citedreferencePassamonti, F., Cervantes, F., Vannucchi, A.M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., Pascutto, C., Lazzarino, M., Cazzola, M. & Tefferi, A. ( 2010 ) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG‐MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 115, 1703 – 1708.en_US
dc.identifier.citedreferenceOken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T. & Carbone, P.P. ( 1982 ) Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5, 649 – 655.en_US
dc.identifier.citedreferenceNguyen, H. & Gotlib, J. ( 2012 ) Insights into the molecular genetics of myeloproliferative neoplasms. In: American Society of Clinical Oncology (ASCO) Education Book, pp. 411 – 418, Available at: http://www.asco.org/ASCOv2/Home/Education%20&%20Training/Educational%20Book/PDF%20Files/2012/zds00112000411.PDF.en_US
dc.identifier.citedreferenceMesa, R.A., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., Tan, A.D., Atherton, P.J., Sloan, J.A. & Tefferi, A. ( 2007 ) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet‐based survey of 1179 MPD patients. Cancer, 109, 68 – 76.en_US
dc.identifier.citedreferenceGangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., Cervantes, F., Passamonti, F. & Tefferi, A. ( 2011 ) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Journal of Clinical Oncology, 29, 392 – 397.en_US
dc.identifier.citedreferenceCuzick, J. ( 2005 ) Forest plots and the interpretation of subgroups. Lancet, 365, 1308.en_US
dc.identifier.citedreferenceCervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. & Tefferi, A. ( 2009 ) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 2895 – 2901.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bjh12274.pdf
Size:
341.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.